Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$24.39 USD
+1.23 (5.31%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $24.40 +0.01 (0.04%) 7:30 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
SMMT 24.39 +1.23(5.31%)
Will SMMT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SMMT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SMMT
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
SMMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
Company News for Sep 10, 2024
Other News for SMMT
Summit Therapeutics files ot sell 10.35M shares of common stock for holders
Summit Therapeutics files to sell 10.35M shares of common stock for holders
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Largest borrow rate increases among liquid names
BioNTech price target raised to $131 from $97 at UBS